Patents by Inventor Xiaojian Jiang

Xiaojian Jiang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240078423
    Abstract: A vision transformer (ViT) is a deep learning model that performs one or more vision processing tasks. ViTs may be modified to include a global task that clusters images with the same concept together to produce semantically consistent relational representations, as well as a local task that guides the ViT to discover object-centric semantic correspondence across images. A database of concepts and associated features may be created and used to train the global and local tasks, which may then enable the ViT to perform visual relational reasoning faster, without supervision, and outside of a synthetic domain.
    Type: Application
    Filed: August 22, 2022
    Publication date: March 7, 2024
    Inventors: Xiaojian Ma, Weili Nie, Zhiding Yu, Huaizu Jiang, Chaowei Xiao, Yuke Zhu, Anima Anandkumar
  • Publication number: 20220162219
    Abstract: The present invention provides novel chiral bisamino-ether compounds, and method of preparation and use thereof. The chiral bisamino-ether compounds have the structure of formula (I). The method of preparation includes: using chiral aminomethanol compounds as starting materials to react with halogenated aryl compounds in the presence of a base to give a variety of chiral bisamino-ether compounds. The novel chiral bisamino-ether compounds can be used for asymmetric fluorocyclization of unsaturated heterocyclic compounds with excellent enantioselectivity and great potentials for industrial applications.
    Type: Application
    Filed: March 5, 2019
    Publication date: May 26, 2022
    Inventors: Xiaojian JIANG, Ying Yeung YEUNG
  • Patent number: 8367720
    Abstract: The present invention relates to an andrographolide derivative of the formula (I), wherein R1, R2 and R3 are same or different substituents selected from hydrogen, substituted or unsubstituted organic acid radicals, inorganic acid radicals, alkyl, aryl or heteroaryl, and at least one of R1, R2 and R3 is R-lipoic acid, S-lipoic acid or a mixture thereof, or corresponding dihydrolipoic acids thereof, or N-acetylcysteine radical. The derivative has good antitumor effect, can induce apoptosis of tumor cells, can directly kill Gram-positive bacteria (staphylococcus aureus) and drug resistance bacteria (MRSA5676 and MRSA5677), can inhibit the QS-system of Gram-negative bacteria (Pseudomonas aeruginosa), can inhibit and destroy the formation of biofilm of Pseudomonas aeruginosa; and exhibits significant hypoglycemic effect, so that it can be used in manufacture of medicaments for treatment of cancers, inflammation, diabetes, and bacterial and viral infections.
    Type: Grant
    Filed: August 7, 2008
    Date of Patent: February 5, 2013
    Assignee: Panorama Research Inc.
    Inventors: Yuqiang Wang, Xiaojian Jiang, Jie Jiang, Zaijun Zhang, Zhaoqi Yang, Pei Yu
  • Publication number: 20110077295
    Abstract: The present invention relates to an andrographolide derivative of the formula (I), wherein R1, R2 and R3 are same or different substituents selected from hydrogen, substituted or unsubstituted organic acid radicals, inorganic acid radicals, alkyl, aryl or heteroaryl, and at least one of R1, R2 and R3 is R-lipoic acid, S-lipoic acid or a mixture thereof, or corresponding dihydrolipoic acids thereof, or N-acetylcysteine radical. The derivative has good antitumor effect, can induce apoptosis of tumor cells, can directly kill Gram-positive bacteria (staphylococcus aureus) and drug resistance bacteria (MRSA5676 and MRSA5677), can inhibit the QS-system of Gram-negative bacteria (Pseudomonas aeruginosa), can inhibit and destroy the formation of biofilm of Pseudomonas aeruginosa; and exhibits significant hypoglycemic effect, so that it can be used in manufacture of medicaments for treatment of cancers, inflammation, diabetes, and bacterial and viral infections.
    Type: Application
    Filed: August 7, 2008
    Publication date: March 31, 2011
    Applicant: PANORAMA RESEARCH INC.
    Inventors: Yuqiang Wang, Xiaojian Jiang, Jie Jiang, Zaijun Zhang, Zhaoqi Yang, Pei Yu
  • Publication number: 20050013792
    Abstract: The present invention relates to liquid sustained release suspension dosage forms comprising ionized forms of water-soluble drugs. In particular, the invention encompasses a liquid form controlled release drug composition comprising a dispersed phase comprising an ion-exchange matrix drug complex comprising a pharmaceutically acceptable ion-exchange matrix and a water-soluble electrolytic drug associated with the ion-exchange matrix, wherein the surface charge of the ion-exchange matrix is opposite that of the electrolytic drug and a dispersion medium substantially free of diffusible counterions, further comprising a polyelectrolyte having the same charge as the electrolytic drug. The invention also provides methods for preparing such compositions and methods of treatment.
    Type: Application
    Filed: November 26, 2003
    Publication date: January 20, 2005
    Inventors: Gary Hollenbeck, Xiaojian Jiang